Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AVP-786 for agitation in Alzheimer's disease dementia
MOH_2024-01-23_012080Phase 3Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AVP-786 with Placebo (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory. Planned start May 2023; status: not yet recruiting.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2024-01-23_012080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-23_012080.